Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.

BMC medical genomics - 11 Feb 2011

Eng Lawson, Ibrahim-zada Irada, Jarjanazi Hamdi, Savas Sevtap, Meschian Mehran, Pritchard Kathleen I, Ozcelik Hilmi

Abstract excerpt

BACKGROUND: Paclitaxel is a microtubule-stabilizing drug that has been commonly used in treating cancer. Due to genetic heterogeneity within patient populations, therapeutic response rates often vary. Here we used the NCI60 panel to identify SNPs associated with paclitaxel sensitivity. Using the panel's GI50 response data available from Developmental Therapeutics Program, cell lines were categorized as either...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Computational Biology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Mutation, Missense

Share to Paclitaxel

Share to Proteins

Share to Software

Share to Tubulin Modulators

Source

Open in PubMed Open full text

Identifiers

PMID: 21314952
DOI: 10.1186/1755-8794-4-18
PMCID: PMC3050680

Genes

GRIK1
SGCD
CFTR
DCT
PTPRD
ROBO1
SNTG1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.PMID 21314952Read ↗

Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.Semantic proximity Read ↗

Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set.Semantic proximity Read ↗

Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine.Semantic proximity Read ↗

Germline pharmacogenetics of paclitaxel for cancer treatment.Semantic proximity Read ↗

Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy.Semantic proximity Read ↗

Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.Semantic proximity Read ↗

Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients.Semantic proximity Read ↗

Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.Semantic proximity Read ↗

Genetic variation that predicts platinum sensitivity reveals the role of miR-193b* in chemotherapeutic susceptibility.Semantic proximity Read ↗

Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity.Semantic proximity Read ↗

A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indicationsSemantic proximity Read ↗

Functional consequences of PRPF39 on distant genes and cisplatin sensitivity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.